Research & Development
Ultromics gains FDA clearance for AI-powered EchoGo to help in the earlier detection of cardiovascular disease
15 November 2019 -

UK-based health technology company Ultromics reported on Thursday the receipt of the US Food and Drug Administration's (FDA) 510(K) clearance for its image cardiac analysis system, EchoGo Core.

Following the FDA's milestone marketing approval, the company will make EchoGo available to clinicians and healthcare providers in the US.

According to the company, EchoGo applies artificial intelligence (AI) to automate the analysis and quantification of ultrasound-based heart scans. The device uses AI to calculate left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

By automating the process and applying its AI analysis to look in greater detail at the scans, EchoGo enables clinicians to interpret echocardiograms efficiently and accurately and assists in their decision-making. The pipeline of AI algorithms underpinning EchoGo was built using thousands of images from a carefully curated dataset, from one of the largest echo studies of its kind.